

INDEX

S.NO.	CONTENTS	P.NO
<u>CHAPTER 1</u>		
Introduction and Literature Survey		
1.1	<u>Introduction</u>	1
1.11	Research envisaged	2
1.12	Proposed plan of work	3
1.2	<u>Profile of 5FU</u>	5
1.21	Description	5
1.22	Physical properties	5
1.23	Stability degradation	6
1.24	Methods of analysis	6
1.25	Mechanism of action	8
1.26	Absorption, fate and excretion	8
1.27	Adverse effects	8
1.28	Therapeutic uses	11
1.3	<u>Profile of MTX</u>	11
1.31	Description	11
1.32	Physical properties	12
1.33	Stability degradation	13
1.34	Methods of analysis	13
1.35	Mechanism of action	17
1.36	Absorption, fate and excretion	17
1.37	Adverse effects	17
1.38	Uses and administration	17

S.NO.	CONTENTS	P.NO
1.4	<u>Profile of cyclophosphamide</u>	18
1.41	Description	18
1.42	Physical properties	19
1.43	Stability degradation	19
1.44	Methods of analysis	19
1.45	Mechanism of action	21
1.46	Absorption, fate and excretion	21
1.47	Adverse effects	21
1.48	Uses and administration	23
1.5	<u>Liposomes as drug delivery systems</u>	23
1.51	Liposomes as carriers in cancer chemotherapy	23
1.52	Liposomes - topical route of administration	26
1.6	<u>References</u>	31

CHAPTER 2

Development of Analytical Methods

2.1	<u>Introduction</u>	41
2.2	<u>Colorimetric methods for 5FU</u>	42
2.21	Materials	42
2.22	Complexation of 5FU with metals of first transition series	43
2.23	Coupling with diazotised aromatic primary amines	62
2.24	Estimation of 5FU as mercuric complex	82
2.25	Reaction of 5FU with paradimethylamino benzaldehyde	95

S.NO.	CONTENTS	P.NO
2.3	<u>Colorimetric methods for estimation of MTX</u>	96
2.31	Materials	96
2.32	Complexation of MTX with metals of first transition series	97
2.33	Reaction of MTX with Folin Ciocalteu reagent	98
2.34	Reaction of MTX with Nessler's reagent	109
2.35	Reaction of MTX with nitric acid	118
2.36	Reaction of MTX with hydroxylamine hydrochloride and ferric chloride	129
2.4	<u>Colorimetric methods for estimation of cyclophosphamide</u>	139
2.41	Materials	139
2.42	Reaction of cyclophosphamide with cobalt-thiocyanate and ferrothiocyanate solutions	139
2.43	Reaction of cyclophosphamide with picric acid	155
2.5	<u>Fluorimetric method of analysis for 5FU</u>	163
2.51	Equipment and operating conditions	164
2.52	Reagents	164
2.53	Scanning of fluorescence of 5FU solutions at different pH values	164
2.54	Development of fluorimetric method for estimation of 5FU in dosage forms	165
2.55	Results and discussion	170
2.6	<u>HPLC method for analysis of 5FU</u>	171
2.61	Experimental	171
2.62	Results and discussion	174

S.NO.	CONTENTS	P.NO
2.7	<u>Estimation of 5FU, MTX and cyclophosphamide in body fluids by proposed analytical methods</u>	184
2.71	Estimation of 5FU in human plasma and rat blood by the proposed analytical methods	184
2.72	Estimation of MTX in human plasma by the proposed analytical methods	190
2.73	Estimation of cyclophosphamide in human plasma by the proposed analytical methods	193
2.8	<u>References</u>	195

CHAPTER 3

Stability Studies

3.1	<u>Introduction</u>	197
3.2	<u>Experimental</u>	199
3.21	Materials	199
3.22	Buffer solutions	199
3.23	Stability studies of 5FU	199
3.24	Stability studies of MTX	213
3.25	Stability studies of 5FU and MTX in semisolid dosage forms	233
3.26	Stability studies of cyclophosphamide	241
3.3	<u>References</u>	258

CHAPTER 4

Liposomes of 5FU and MTX for skin targetting

4.1	<u>Introduction</u>	259
4.2	<u>Experimental</u>	259
4.21	Apparatus and equipments	259
4.22	Materials	260

S.NO.	CONTENTS	P.NO
4.23	Analytical methods	260
4.24	Preparation of liposomes of 5FU and MTX	269
4.25	<u>In vitro</u> permeation studies	281
4.26	Stability studies	285
4.3	<u>Results and discussion</u>	292
4.4	<u>In vivo methods</u>	312
4.41	Experimental	313
4.42	Results and discussion	317
4.5	<u>References</u>	328

CHAPTER 5

Summary and Conclusions

5.1	<u>Development of analytical methods</u>	330
5.11	Colorimetric methods	330
5.12	Flourimetric method for 5FU	337
5.13	High performance liquid chromatographic method	337
5.14	<u>In vitro</u> estimation of 5FU, MTX and cyclophosphamide in human plasma	338
5.15	<u>In vivo</u> estimation of 5FU from rat blood	338
5.2	<u>Accelerated stability studies</u>	339
5.21	Stability studies of 5FU	339
5.22	Stability studies of MTX	340
5.23	Stability studies of 5FU and MTX in semisolid dosage forms	341
5.24	Stability studies of cyclophosphamide	341
5.3	<u>Liposomes of 5FU and MTX for skin targetting</u>	342
	<u>List of Publications</u>	347